发明名称 |
FcgammaRIIb-specific Fc region variant |
摘要 |
(Problem) To provide: a Fc region variant which has such a property that the binding activity to FcγRIIb is increased and/or the binding selectivity to FcγRIIb compared with that to FcγRIIa (type R) is increased when compared with a polypeptide that contains a Fc region having no amino acid modification introduced thereinto; a polypeptide containing the Fc region variant; a pharmaceutical composition containing the polypeptide; a therapeutic or prophylactic agent for immune inflammatory diseases, which comprises the pharmaceutical composition; methods for producing the aforementioned products; and a method for increasing the binding activity to FcγRIIb and also increasing the binding selectivity to FcγRIIb compared with that to FcγRIIa (type R). (Solution) It is found that a polypeptide which contains an antibody Fc region variant comprising an amino acid sequence containing the combination of the amino acid modification at position-238 as numbered in accordance with the EU numbering method and the amino acid modification at another specific position has such a property that the binding activity to FcγRIIb is increased and/or the binding selectivity to FcγRIIb compared with that to FcγRIIa (type R) is increased. |
申请公布号 |
AU2013306700(A1) |
申请公布日期 |
2015.02.12 |
申请号 |
AU20130306700 |
申请日期 |
2013.08.23 |
申请人 |
CHUGAI SEIYAKU KABUSHIKI KAISHA |
发明人 |
KATADA, HITOSHI;KADONO, SHOJIRO;MIMOTO, FUTA;IGAWA, TOMOYUKI |
分类号 |
C12N15/09;A61K39/395;A61K47/42;C07K16/28;C07K19/00 |
主分类号 |
C12N15/09 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|